COMPOSITION AND PROCESS FOR THE CARE OF KERATINOUS MATERIALS

Abstract

COMPOSITION AND METHOD FOR THE TREATMENT OF KERATINOUS MATERIALS The present invention relates to a composition comprising: (i) at least one copper peptide complex; (ii) at least one C-glycoside; and (iii) a sugar fatty acid ester and / or an oxyalkylated ether thereof. The present invention also relates to a non-therapeutic method for the treatment of keratinous materials, comprising the application of said composition to the keratinous materials. Figure for the abstract: none

Description

Title of the invention: COMPOSITION AND METHOD FOR THE CARE OF KERATINOUS MATERIALS technical field

[0001] The present invention relates to a cosmetic composition. In particular, the present invention relates to a keratinous material care composition. The present invention also relates to a non-therapeutic method for caring for keratinous materials. STATE OF THE ART

[0002] Human skin consists of three compartments, namely a superficial compartment, which is the epidermis, the dermis and a deep compartment, which is the hypodermis.

[0003] The dermis is primarily composed of fibroblasts and an extracellular matrix (ECM). This extracellular matrix consists of various macromolecules responsible for the skin's mechanical resistance, suppleness, tone, and elasticity, as well as physiologically important functions (hydration, thermoregulation, and regulation of skin permeability). These macromolecules include, in particular, collagens, elastin, and glycoconjugates (glycoproteins and proteoglycans).

[0004] Collagens represent 70% of the proteins in the ECM. Naturally, collagens are constantly renewed, but this renewal decreases with age, resulting in thinning of the dermis.

[0005] A wide variety of cosmetic products have been used to care for the skin, for example, to combat skin aging. However, some anti-aging cosmetic products on the market are unsatisfactory; for example, they are not stable and / or do not have a desired appearance, such as a translucent appearance.

[0006] Thus, there is always a need to formulate a care composition for keratinous materials, for example to resist the aging of keratinous materials, which is stable, and preferably has a translucent appearance. Summary of the invention

[0007] An object of the present invention is therefore to develop a keratinous material care composition, for example anti-aging, which is stable, and preferably has a translucent appearance.

[0008] Another object of the present invention is to propose a non-therapeutic method for the treatment of keratinous materials.

[0009] Consequently, in a first aspect, the present invention proposes a composition comprising: i. at least one copper peptide complex; ii. at least one C-glycoside; and iii. a sugar fatty acid ester and / or an oxyalkylated ether thereof.

[0010] The inventors have found that the composition of the present invention is stable and preferably has a translucent appearance.

[0011] The composition of the present invention can be used to resist the aging of keratinous materials.

[0012] In a second aspect, the present invention proposes a non-therapeutic method for the treatment of keratinous materials, comprising the application of the composition according to the first aspect of the present invention on the keratinous materials.

[0013] Other subjects, features, aspects, and advantages of the present invention will be presented in the following description and will be partly evident from the description or may be learned through practice of the present invention. DETAILED DESCRIPTION OF THE INVENTION

[0014] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as that commonly understood by a person skilled in the art of the present invention. Where the definition of a term in this description conflicts with the meaning commonly understood by a person skilled in the art of the present invention, the definition described herein shall apply.

[0015] In what follows and unless otherwise indicated, the limits of a range of values ​​are included in that range, in particular, in the expressions "between...and..." and "from...to...".

[0016] Furthermore, the expression "at least one" used in this description is equivalent to the expression "one or more".

[0017] Throughout this application, the term "including" shall be interpreted as encompassing all the specifically mentioned features as well as optional, additional, unspecified features. As used herein, the use of the term "including" also discloses the embodiment in which no features other than the specifically mentioned features are present (i.e., "consisting of").

[0018] Unless otherwise specified, all numerical values ​​expressing a quantity of ingredients and the like used in the description and claims shall be understood as modified by the term "approximately". Accordingly, unless otherwise indicated, the numerical values ​​and parameters described These are approximate values ​​which, if necessary, can be changed according to the desired objective.

[0019] For the purposes of the present invention, the term "keratinous materials" is intended to cover human skin, including facial skin and lips. Facial skin is considered in particular according to the present invention.

[0020] In the present invention, all percentages refer, unless otherwise specified, to a percentage by weight.

[0021] According to the first aspect, the composition of the present invention comprises: i. at least one copper peptide complex; ii. at least one C-glycoside; and iii. a sugar fatty acid ester and / or an oxyalkylated ether thereof. Copper peptide complexes

[0022] According to the first aspect, the composition of the present invention comprises at least one copper peptide complex.

[0023] As used herein, the expression "copper peptide complex" generally refers to a coordination compound comprising a peptide molecule and a copper(II) ion not covalently complexed therewith. As is well understood in the art, copper(II) denotes a copper ion having a valence of 2 (i.e., Cu + 2). The peptide molecule acts as a complexing agent by donating electrons to the copper ion to produce the non-covalent complex. The peptide molecule is a chain of two or more amino acid motifs or amino acid-derived motifs covalently linked to each other via amide bonds (e.g., -CONH-), the formation of such bonds being accompanied by the elimination of water.

[0024] Generally, an amino acid consists of an amino group, a carboxyl group, a hydrogen atom, and a portion of an amino acid side chain, all linked, in the case of an alpha-amino acid, to a single carbon atom called the alpha carbon. Amino acid motifs may be provided by amino acids other than alpha-amino acids. For example, amino acids may be beta- or gamma-amino acids, such as those shown below. NILE H—C—COOH

[0025] alpha-amino acid nh2 H—Ç—(3¾—CO0I1

[0026] beta-amino acid NH2 FI—c—CH2—Œ2““COOn

[0027] gamma-amino acid

[0028] where X is the fraction of amino acid side chain bonded, with the amino group and hydrogen, to a carbon atom in alpha, beta or gamma.

[0029] By way of further example, amino acids include, but are not limited to, natural alpha-amino acids. Natural amino acids are those from which the amino acid motifs of natural proteins are derived. Some of these amino acids, along with their respective amino acid side-chain fractions, are listed below in Table 1. The natural amino acids listed are all in the L configuration, with reference to the optical orientation of the alpha carbon or other carbon atom bearing the amino acid side chain. A peptide molecule of the present invention may also comprise amino acids that are in the D optical configuration, or a mixture of D and L amino acids.

[0030] [Tables 1] Side Chain Fractions of Natural Amino Acids Side Chain Fraction of Amino Acids Amino Acid —H Glycine —ch3 Alanine —CH(CH3)2 Valine —CH2CH(CH3)2 Leucine —CH(CH3)CH2CH3 Isoleucine —(CH2)4NH3+ Lysine —(CH2)3NHC(NH2)NH2+ Arginine Histidine —CH2COO— Aspartic acid —CH2CH2COO— Glutamic acid —ch2conh2 Asparagine —ch2ch2conh2 Glutamine —CH2— Phenylalanine Ci h---° H Tyrosine ******* CH ih H Tryptophan —ch2sh Cysteine ​​—ch2ch2sch3 Methionine —ch2oh Serine —CH(OH)CH3 Threonine ch2----CH2 cA J XNH Proline

[0031] Other natural amino acids include hydroxyproline and gamma-carboxyglutamate.

[0032] Representative amino acid derivatives include those shown in Table 2 below. —(CH2)nCH(CH3)(CH2)mCH3 where n, m = 0-20 (when n = 0, m 0 or 1 and when n = 1, m 0) —(CH2)nNH2where n = 1-20 (n 4) —(CH2)nCONH2 where n = 3-20 —(CH2)nCOOH where n = 3-20 where n = 2-20 ---iCÎL b. where n = 2-20 where n = 2-20 OH —(CH2)nSH where n = 2-20 —(CH2)nS(CH2)mCH3 where n, m = 1-20 (when n = 2, m 0) —(CH2)nCH2OH where n = 1-20 —(CH2)nCH(CH3)OH where n = 1-20 And where Xi = H or the following fractions: —(CH2)nCH3 where n = 0-20 —(CH2)nCH(CH3)(CH2)mCH3where n, m = 0-20

[0034] Histidine derivatives include compounds with the following structures: NIL CH—COOH 1CH2K y2

[0035] wherein n = 1-20, and Yi and Y2 are independently chosen from alkyl fractions containing 1 to 12 carbon atoms or an aryl fraction containing 6 to 12 carbon atoms. In some embodiments, n is 1, Y2 is methyl, and Yi is H (i.e., 3-methylhistidyl) or Y2 is H and Yi is methyl (i.e., 5-methylhistidine).

[0036] Similarly, arginine derivatives include structural compounds: NH2--CH—ÇOOH ((¾ NH C=NH NILE

[0037] where n= 1-20 (except n=3).

[0038] As used herein, "alkyl" means a straight-chain or branched aliphatic hydrocarbon, cyclic or non-cyclic, substituted or unsubstituted, saturated or unsaturated, containing from 1 to 18 carbon atoms. Representative saturated straight-chain alkyls include methyl, ethyl, n-propyl, and the like, while saturated branched alkyls include isopropyl, sec-butyl, isobutyl, tert-butyl, isopentyl, and the like. Representative saturated cyclic alkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like; while unsaturated cyclic alkyls include cyclopentenyl, cyclohexenyl, and the like. Unsaturated alkyls contain at least one double or triple bond between adjacent carbon atoms (referred to respectively as "alkenyl" or "alkynyl").Representative alkenyls include ethenyl, 1-butenyl, isobutenyl, 2-methyl-2-butenyl, and similar compounds; while representative alkynyls include acetylenyl, 2-butynyl, 3-methyl-1-butynyl, and similar compounds.

[0039] Furthermore, as used herein, "aryl" means an aromatic carbocyclic fraction such as phenyl or naphthyl, and may be substituted or unsubstituted. "Arylalkyl" as used herein means an alkyl having at least one alkyl hydrogen atom replaced by a substituted or unsubstituted aryl fraction, such as benzyl (i.e., -CH2-phenyl, -(CH2)2-phenyl, -(CH2)3-phenyl, -CH(phenyl)2, and the like).

[0040] A copper peptide complex of the present invention may correspond to the formula [Ri-R2-R3]:copper(II) where R3 is at least one amino acid or an amino acid derivative, as defined above, linked to R2 by a peptide bond (i.e., —C(=O)NH₂-). When R3 is a single amino acid or amino acid derivative, then the peptide of the copper peptide complex is generally classified as a tripeptide. As another example of a copper peptide complex of the present invention corresponding to the formula [RrR2-R3]:copper(II), R3 is a chemical fraction linked to the fraction R2 by an amide bond. The expression "chemical fraction," as used here and with reference to R3, includes any chemical fraction having an amino group capable of forming an amide bond with the carboxyl termination of R2 (i.e., the carboxyl termination of histidine, arginine, or their derivatives).

[0041] By way of a more specific example, where R3 is a chemical fraction linked to fraction R2 by an amide bond, R3 is —NH2, an alkylamino fraction having from 1 to 20 carbon atoms, or an arylamino fraction having from 6 to 20 carbon atoms. As used herein, an “alkylamino fraction” encompasses alkyl fractions containing an amino fraction, in which the alkyl fraction is as defined above, and includes, but is not limited to, octylamine and propylamine. Similarly, an “arylamino fraction” encompasses aryl fractions containing an amino fraction, in which the aryl fraction is as defined above, and includes, but is not limited to, benzylamine and benzyl-(CH2)M4-amine. Other examples of suitable chemical fractions having amino groups capable of forming an amide bond with the carboxyl terminus of R2 include polyamines such as spermine and spermidine.

[0042] It should be understood that R3 may include more than one chemical fraction. For example, additional amino acids or amino acid derivatives may be linked to the copper peptide complexes comprising the tripeptides described above to generate copper peptide complexes comprising peptides having four or more amino acids and / or amino acid derivatives. For illustrative purposes, Table 3, shown below, presents various representative examples of copper peptide complexes used in or included in embodiments of the present invention.

[0043] [Tables3] Representative peptide-copper complexes Examples of [Ri—R2]: copper(II) glycylhistidine: copper alanylhistidine: copper glycyl-(3-methyl)histidine: copper alanyl-(3-methyl)histidine: copper glycyl-(5-methyl)histidine: copper alanyl-(5-methyl)histidine: copper glycyl-arginine: copper alanyl-arginine: copper (N-methyl)glycine-histidine: copper (N-methyl)glycine-arginine: copper Examples of [Ri—R2—R3]: copper(II) where R3 is a chemical fraction linked by an amide bond glycylhistidyl-NH2: copper glycyl-arginyl-NH2: copper glycyl-(3-methyl)histidyl-NH2: copper alanyl-(3-methyl)histidyl-NH2: copper glycyl-arginyl-NH2: copper alanyl-arginyl-NH2: copper (N-methyl)glycine-histidyl-NH2: copper (N-methyl)glycine-arginyl-NH2: copper glycyl-histidyl-NHoctyl: copper glycyl-arginyl-NHoctyl: copper Examples of [Ri—R2—R3]: copper(II) where R3 is an amino acid or amino acid derivative linked by a peptide bond glycyl-histidyl-lysine: copper glycyl-arginyl-lysine: copper glycyl-(3-methyl)histidyl-lysine: copper glycyl-(5-methyl)histidyl-lysine: copper alanyl-histidyl-lysine: copper alanyl-arginyl-lysine: copper alanyl-(3-methyl)histidyl-lysine: copper alanyl-(5-methyl)histidyl-lysine: copper glycyl-histidyl-phenylalanine: copper glycyl-arginyl-phenylalanine: copper glycyl-(3-methyl)histidyl-phenylalanine: copper glycyl-(5-methyl)histidyl-phenylalanine: copper alanyl-histidyl-phenylalanine: copper alanyl-arginyl-phenylalanine: copper alanyl-(3-methyl)histidyl-phenylalanine: copper alanyl-(5-methyl)histidyl-phenylalanine: copper glycyl-histidyl-lysyl-phenylalanyl-phenylalanine: copperglycyl-arginyl-lysyl-phenylalanyl-phenylalanyl: copper; glycyl-(3-methyl)histidyl-lysyl-phenylalanine: copper; glycyl-(5-methyl)histidyl-lysyl-phenylalanine: copper; (N-methyl)glycyl-histidyl-lysine: copper; (N-methyl)glycyl-arginyl-lysine: copper; valyl-histidyl-lysine: copper; glycyl-histidyl-lysyl-prolyl-phenylalanyl-proline: copper; prolyl-histidyl-lysine: copper; leucyl-histidyl-lysine: copper; glycyl-D-histidyl-L-lysine: copper; seryl-histidyl-lysine: copper

[0044] Other examples of copper peptide complexes enclosed in embodiments of the present invention are disclosed in US patents Nos. 4,665,054; 4,760,051; 4,767,753; 4,810,693; 4,877,770; 5,023,237; 5,059,588; 5,118,665; 5,120,831; 5,164,367; 5,177,061; 5,214,032; 5,538,945; 5,550,183; and 6,017,888, all of which are incorporated herein by reference in their entirety.

[0045] Examples of copper peptide complex derivatives, encompassed in embodiments of the present invention, include, but are not limited to, those disclosed and described in the aforementioned US patents relating to copper peptide complexes, as well as those disclosed and described in the published PCT application bearing the International publication number WO 94 / 03482, incorporated herein by reference in its entirety.

[0046] Preferably, the peptide in the copper peptide complex comprises at least two amino acid motifs, preferably three amino acid motifs, covalently linked together via amide bonds, and the amino acid motifs are selected from glycine, alanine, valine, leucine, isoleucine, lysine, arginine, histidine, aspartic acid, glutamic acid, asparagine, glutamine, phenylalanine, tyrosine, tryptophan, cysteine, methionine, serine, threonine, proline, hydroxyproline and gamma-carboxyglutamate.

[0047] Preferably, the peptide-to-copper molar ratio in the copper-peptide complex ranges from about 1:1 to about 3:1.

[0048] Preferably, the copper peptide complex is selected from glycyl-histidyl-lysine:copper, glycyl-arginyl-lysine:copper, glycyl-(3-methyl)histidyl-lysine:copper, glycyl-(5-methyl)histidyl-lysine:copper, alanyl-histidyl-lysine:copper, alanyl-arginyl-lysine:copper, alanyl-(3-methyl)histidyl-lysine:copper, alanyl-(5-methyl)histidyl-lysine:copper, glycyl-histidyl-phenylalanine:copper, glycyl-arginyl-phenylalanine:copper, glycyl-(3-methyl)histidyl-phenylalanine:copper, glycyl-(5-methyl)histidyl-phenylalanine:copper, alanyl-histidyl-phenylalanine:copper, alanyl-arginyl-phenylalanine: copper, alanyl-(3-methyl)histidyl-phenylalanine: copper, alanyl-(5-methyl)histidyl-phenylalanine: copper, (N-methyl)glycyl-histidyl-lysine: copper, (N-methyl)glycyl-arginyl-lysine: copper, valyl-histidyl-lysine: copper, prolyl-histidyl-lysine: copper, leucyl-histidyl-lysine: copper, glycyl-D-histidyl-lysine: copper, seryl-histidyl-lysine: copperand their combinations.

[0049] More preferably, the copper peptide complex is chosen from L-alanyl-L-histidyl-L-lysine: copper (II) (“AHK-Cu”), L-valyl-L-histidyl-L-lysine: copper (II) (“VHK-Cu”), glycyl-L-histidyl-L-lysine: copper (II) (“GHK-Cu”), and their combinations.

[0050] Most preferably, the composition according to the present invention comprises copper tripeptide-1.

[0051] Advantageously, the copper peptide complex is present in the composition of the present invention in an amount ranging from 0.00001% by weight to 10% by weight, preferably from 0.0005% by weight to 5% by weight, more preferably from 0.001% by weight to 1% by weight, even more preferably from 0.001% by weight to 0.5% by weight, still more preferably from 0.003% by weight to 0.3% by weight, most preferably from 0.005% by weight to 0.2% by weight, relative to the total weight of the composition. C-glycosides

[0052] According to the first aspect, the composition of the present invention comprises at least one C-glycoside.

[0053] Preferably, the C-glycoside is chosen from compounds of formula (I): zX-R (I) S---7 (D

[0054] in which:

[0055] - R represents a saturated alkyl radical in C1 to C1, in particular in C1 to C4, which can optionally be substituted by at least one radical chosen from OH, COOH or COOR"2, R"2 being a saturated CrC4 alkyl radical,

[0056] - S represents a monosaccharide or polysaccharide comprising up to 20 sugar motifs, in particular up to 6 sugar motifs, in the form of pyranose and / or furanose and of the L and / or D series, knowing that said monosaccharide or polysaccharide may be substituted by a hydroxyl group which is necessarily free and optionally one or more optionally protected amine functional groups, and

[0057] - X represents a radical chosen from the groups -CO-, -CH(OH)-, -CH(NH2)-, - CH(NHCH2CH2CH2OH)-, -CH(NHPh)- and -CH(CH3)- and in particular a radical -CO-, -CH(OH)- or -CH(NH2)- and more particularly a radical -CH(OH)-,

[0058] the S-CH2-X bond represents a C-anomeric bond, which can be α or [3, and also their physiologically acceptable salts, their solvates, such as hydrates, and their optical and geometric isomers.

[0059] The C-glycosides used for the implementation of the invention are in particular those for which R designates a linear alkyl radical saturated in Ci-C6, in particular in Ci-C4, preferably in CrC2 and more preferably, a methyl radical.

[0060] In particular, alkyl groups suitable for implementing the invention include methyl, ethyl, isopropyl, n-propyl, n-butyl, t-butyl, isobutyl, sec-butyl, pentyl, n-hexyl, cyclopropyl, cyclopentyl or cyclohexyl.

[0061] According to one embodiment of the invention, a C-glycoside corresponding to formula (I) can be used, for which S can represent a monosaccharide or a polysaccharide comprising up to 6 sugar motifs, in the form of pyranose and / or furanose and of the L and / or D series, said monosaccharide or polysaccharide having at least one necessarily free hydroxyl functional group and / or optionally one or more necessarily protected amine functional groups, X and R otherwise retaining all the above definitions.

[0062] Advantageously, a monosaccharide of the invention can be selected from D-glucose, D-galactose, D-mannose, D-xylose, D-lyxose or L-fucose, L-arabinose, L-rhamnose, D-glucuronic acid, D-galacturonic acid, D-iduronic acid, N-acetyl-D-glucosamine or N-acetyl-D-galactosamine and advantageously designates D-glucose, D-xylose, N-acetyl-D-glucosamine or L-fucose and in particular D-xylose.

[0063] More particularly, a polysaccharide of the invention comprising up to 6 sugar motifs can be selected from D-maltose, D-lactose, D-cellobiose, D-maltotriose, a disaccharide combining a uronic acid selected from D-iduronic acid or D-glucuronic acid with a hexosamine selected from D-galactosamine, D-glucosamine, N-acetyl-D-galactosamine or N-acetyl-D-glucosamine, an oligosaccharide comprising at least one xylose which can advantageously be selected from xylobiose, methyl-[3-xylobioside, xylotriose, xylotetraose, xylopentaose and xylohexaose, and in particular xylobiose, which is composed of two xylose molecules linked via a 1-4 bond.

[0064] More particularly, S can represent a monosaccharide chosen from D-glucose, D-xylose, L-fucose, D-galactose or D-maltose and in particular D-xylose.

[0065] Preferably, a C-glycoside of formula (I) is used, for which:

[0066] - R denotes an alkyl radical in the Ci-C4 form, in particular in the linear unsubstituted Ci-C2 form, including a methyl radical;

[0067] - S represents a monosaccharide as described above and chosen in particular among D-glucose, D-xylose, N-acetyl-D-glucosamine or L-fucose, and in particular D-xylose;

[0068] - X represents a group chosen from -CO-, -CH(OH)- or -CH(NH2)- and, of preferably a -CH(OH)- group.

[0069] Acceptable salts of the compounds described in the present invention include conventional non-toxic salts of said compounds, such as those formed from organic or inorganic acids. Examples include salts of inorganic acids such as sulfuric acid and hydrochloric acid. Examples also include salts of organic acids, which may comprise one or more carboxylic, sulfonic, or phosphonic acid groups. In particular, examples include propionic acid, acetic acid, terephthalic acid, citric acid, and tartaric acid.

[0070] When the compound of formula (I) comprises an acid group, the neutralization of the acid group(s) can be carried out with an inorganic base, such as LiOH, NaOH, KOH, Ca(OH)2, NH4OH, Mg(OH)2 or Zn(OH)2, or with an organic base, such as a primary, secondary or tertiary alkylamine, for example triethylamine or butylamine. This primary, secondary or tertiary alkylamine may comprise one or more nitrogen and / or oxygen atoms and may therefore comprise, for example, one or more alcohol functional groups; examples include 2-amino-2-methylpropanol, triethanolamine, 2-(dimethylamino)propanol or 2-amino- 2-(hydroxymethyl)-l,3-propanediol. Lysine or 3-(dimethylamino)propylamine can also be mentioned.

[0071] Solvates that are acceptable for the compounds described in the present invention include conventional solvates, such as those formed during the final stage of preparation of said compounds due to the presence of solvents. Examples include solvates due to the presence of water or linear or branched alcohols, such as ethanol or isopropanol.

[0072] Of course, according to the invention, a C-glycoside corresponding to formula (I) can be used alone or in a mixture with other C-glycosides and in any proportion.

[0073] A C-glycoside suitable for the invention can in particular be obtained by the synthesis process described in document WO 02 / 051828.

[0074] By way of non-limiting illustration of C-glycoside compounds that are particularly suitable for the invention, the following compounds may be cited in particular:

[0075] - C-[3-D-xylopyranoside-n-propan-2-one,

[0076] - C-a-D-xylopyranoside-n-propan-2-one,

[0077] - C-[3-D-xylopyranoside-2-hydroxypropane,

[0078] - C-a-D-xylopyranoside-2-hydroxypropane,

[0079] - l-(C-[3-D-fucopyranoside)propan-2-one,

[0080] - l-(C-a-D-fucopyranoside)propan-2-one,

[0081] - l-(C-[3-L-fucopyranoside)propan-2-one,

[0082] - l-(C-a-L-fucopyranoside)propan-2-one,

[0083] - l-(C-[3-D-fucopyranoside)-2-hydroxypropane,

[0084] - l-(C-a-D-fucopyranoside)-2-hydroxypropane,

[0085] - l-(C-[3-L-fucopyranoside)-2-hydroxypropane,

[0086] - l-(C-a-L-fucopyranoside)-2-hydroxypropane,

[0087] - l-(C-[3-D-glucopyranosyl)-2-hydroxypropane,

[0088] - l-(C-a-D-glucopyranosyl)-2-hydroxypropane,

[0089] - l-(C-[3-D-galactopyranosyl)-2-hydroxypropane,

[0090] - l-(CaD-galactopyranosyl)-2-hydroxypropane,

[0091] - l-(C-[3-D-fucofuranosyl)propan-2-one,

[0092] - l-(CaD-fucofuranosyl)propan-2-one,

[0093] - l-(C-[3-L-fucofuranosyl)propan-2-one,

[0094] - l-(CaL-fucofuranosyl)propan-2-one,

[0095] - C-[3-D-maltopyranoside-n-propan-2-one,

[0096] - CaD-maltopyranoside-n-propan-2-one,

[0097] - C-[3-D-maltopyranoside-2-hydroxypropane,

[0098] - CaD-maltopyranoside-2-hydroxypropane, their isomers and mixtures thereof.

[0099] According to one embodiment, C-[3-D-xylopyranoside-2-hydroxypropane or CaD-xylopyranoside-2-hydroxypropane and even better C-[3-D-xylopyranoside-2-hydroxypropane can be advantageously used for the composition according to the invention.

[0100] Most preferably, the composition according to the present invention comprises C-[3-D-xylopyranoside-2-hydroxypropane (or hydroxypropyl tetrahydropyrantriol).

[0101] Advantageously, the C-glycoside is present in the composition according to the present invention in an amount ranging from 0.01% by weight to 20% by weight, preferably from 0.1% by weight to 15% by weight, more preferably from 0.3% by weight to 10% by weight, even more preferably from 0.5% by weight to 5% by weight, relative to the total weight of the composition.

[0102] Sugar fatty acid esters and / or their oxyalkylated ethers

[0103] According to the first aspect, the composition of the present invention comprises a sugar fatty acid ester and / or an oxyalkylated ether thereof.

[0104] The sugar fatty acid ester may be an ester of various types of fatty acids and sugars, provided that the ester is cosmetically or dermatologically acceptable. As used here, the expression "cosmetically acceptable" or "dermatologically acceptable" is intended to mean that a composition is suitable for use in contact with human tissues such as keratinous materials and mucous membranes without toxicity, incompatibility, instability, and / or excessive allergic response.

[0105] The sugar fatty acid ester is preferably a monoester or diester of a sugar. "Sugar," as used herein, is understood to include oxygen-containing hydrocarbon compounds possessing multiple alcohol functional groups, with or without aldehyde or ketone functional groups, and containing at least four carbon atoms. These sugars may be monosaccharides, oligosaccharides, or polysaccharides.

[0106] Suitable sugars include, for example, sucrose, glucose, galactose, ribose, fucose, maltose, fructose, mannose, arabinose, xylose, lactose, and their derivatives, for example, alkylated derivatives such as methyl derivatives like methylglucose. Preferably, the sugar is glucose or its alkylated derivative such as an alkylglucose. As used here, (alkyl)glucose is understood to include glucose, an alkylglucose, and a mixture of glucose and an alkylglucose.

[0107] As suitable sugar fatty acid esters for the composition according to the present invention, examples may be given to the sugar esters described above, in particular an (alkyl)glucose and linear or branched fatty acids, saturated or unsaturated in C6-C30, such as fatty acids in Ci2-C22. If unsaturated, these compounds may have one to three conjugated or non-conjugated carbon-carbon double bonds.

[0108] Esters can also be selected from mono-, di-, tri- and tetra-esters, polyesters, and their mixtures.

[0109] These esters may be, for example, oleate, laurate, palmitate, myristate, behenate, cocoate, stearate, linoleate, linolenate, caprate, arachidonates or mixtures thereof such as oleopalmitate, oleostearate, mixed palmito-stearate esters.

[0110] For example, in the present invention, mono- and di-esters can be used. Preferably, the sugar fatty acid ester is chosen from mono- or di-oleate, stearate, behenate, oleopalmitate, linoleate, linolenate, oleostearate, sucrose, glucose, and methylglucose.

[0111] The oxyalkylated ether of a sugar fatty acid ester may include from about 1 to about 200, preferably from about 10 to about 100, more preferably from about 15 to about 50, moles of an oxyalkylated group, including all intermediate ranges and subranges.

[0112] Preferably, the oxyalkylated ether of a sugar fatty acid ester has about 1 to about 200, preferably about 10 to about 100, more preferably about 15 to about 50 moles of ethylene oxide, propylene oxide, or mixtures thereof, including all intermediate ranges and sub-ranges.

[0113] Preferably, the oxyalkylated ether of a sugar fatty acid ester has from about 1 to about 200, preferably from about 10 to about 100, more preferably from about 15 to about 50 moles of ethylene oxide, including all intermediate ranges and sub-ranges.

[0114] Oxyalkylated sugar fatty acid ester ethers that may preferably be used in the present invention include, for example, oxyethylened fatty acid and methyl glucose ethers, such as a polyethylene glycol ether of a methyl glucose and stearic acid diester containing about 20 moles of ethylene oxide (INCI name: PEG-20 methyl glucose distearate), a polyethylene glycol ether of a mixture of methyl glucose and stearic acid monoester and diester containing about 20 moles of ethylene oxide (INCI name: PEG-20 methyl glucose sesquistearate, such as Glucamate® SSE-20 sold by Lubrizol), and polyglyceryl-3 methyl glucose distearate, such as TEGO CARE 450 MB sold by EVONIK GOLDSCHMIDT. Oxyalkylated ethers can be used alone or in combination.

[0115] Preferably, the oxyalkylated ether of a sugar fatty acid ester is selected from ethoxylated and / or propoxylated (alkyl)glucose fatty acid esters. Among the ethoxylated (alkyl)glucose fatty acid esters, an ethoxylated (alkyl)glucose stearate, in particular, PEG-20 methyl glucose sesquistearate, is preferred. Among the esters of propoxylated (alkyl)glucose fatty acids, a propoxylated (alkyl)glucose stearate, in particular polyglyceryl-3 methylglucose distearate, is preferred.

[0116] Preferably, the sugar fatty acid ester and / or an oxyalkylated ether thereof is selected from the esters of linear or branched C6-C30 (alkyl)glucose and fatty acids, saturated or unsaturated, and their oxyalkylated ethers.

[0117] More preferably, the sugar fatty acid ester and / or an oxyalkylated ether thereof is chosen from methylglucose and Ci2-C221 linear or branched fatty acid esters, saturated or unsaturated, and their ethoxylated and / or propoxylated ethers.

[0118] Most preferably, the composition according to the present invention comprises at least one of methyl glucose sesquistearate, PEG-20 methyl glucose sesquistearate, polyglyceryl-3 methylglucose distearate, and combinations thereof.

[0119] Advantageously, the sugar fatty acid ester and / or an oxyalkylated ether thereof is present in the composition of the present invention in an amount ranging from 0.01% to 10% by weight, preferably from 0.02% to 5% by weight, more preferably from 0.05% to 3% by weight, even more preferably from 0.05% to 1% by weight, relative to the total weight of the composition. Hydrophilic polymers

[0120] Preferably, the composition of the present invention comprises one or more hydrophilic polymers.

[0121] The expression "hydrophilic polymer" means, in the context of the present invention, a water-dispersible polymer.

[0122] The hydrophilic polymer(s) used in the context of the present invention is / are not amphiphilic. They are devoid of a part that is lipophilic (that retains fatty substances) and nonpolar, in particular devoid of fatty chains.

[0123] The hydrophilic polymer(s) may in particular be chosen from:

[0124] 1) homopolymers or copolymers of acrylic acid, which are preferably cross-linked, and their salts such as the products sold under the name Carbopol® (INCI name: carbomer) by the company Lubrizol; we can in particular mention the commercial references Carbopol® 910, 934, 940, 941, 934 P and 981.

[0125] 2) polyacrylate salts.

[0126] These include neutralized polymers, crosslinked or uncrosslinked, in particulate or non-particulate form. Advantageously, sodium salts are preferred. For example, polymers bearing the INCI name sodium polyacrylate may be cited.

[0127] 3) 2-acrylamido-2-methylpropanesulfonic acid polymers and copolymers (AMPS®), which are optionally cross-linked and / or neutralized, selected from:

[0128]

[0129]

[0130]

[0131]

[0132]

[0133]

[0134] a. Poly(2-acrylamido-2-methylpropanesulfonic acid) polymers, in particular homopolymers, polyAMPS®, which are crosslinked and neutralized to at least 90%. They are generally characterized by the fact that they include, distributed randomly: i. from 90% to 99.9% by weight of motifs of general formula (1) below: in in which X+ denotes a cation or a mixture of cations, knowing that at least 10 mol% of the X+ cations may be H+ protons; and i. from 0.01% to 10% by weight of crosslinking motifs from at least one monomer containing at least two olefinic double bonds; the weight proportions being defined in relation to the total weight of the polymer. This polymer preferably comprises 98% to 99.5% by weight of formula (1) motifs and 0.2% to 2% by weight of crosslinking motifs. The X+ cation represents a cation or mixture of cations chosen specifically from among a proton, an alkali metal cation, a cation equivalent to that of an alkaline earth metal, or an ammonium ion. The preferred X+ cation is the NH4+ cation. More specifically, 90 to 100 mol% of the cations are NH4+ cations and 0 to 10 mol% are protons (H+). Crosslinking monomers containing at least two olefinic double bonds are selected, for example, from dipropylene glycol diallyl ether, polyglycol diallyl ethers, triethylene glycol divinyl ether, hydroquinone diallyl ether, tetraallyloxyethane or other polyfunctional ethers of allylic or vinyl alcohol, tetraethylene glycol diacrylate, triallylamine, trimethylolpropane diallyl ether, methylenebisacrylamide or divinylbenzene. Crosslinking monomers containing at least two olefinic double bonds are particularly chosen from those corresponding to the general formula (2) below: CH$ (2ï

[0135]

[0136]

[0137]

[0138]

[0139]

[0140]

[0141]

[0142] in which Ri denotes hydrogen atony or an alkyl radical in Ci-C4 and higher particularly the methyl radical (trimethylolpropane triacrylate). One such polymer that can be cited is the crosslinked and neutralized 2-acrylamido-2-methylpropanesulfonic acid homopolymer sold by Clariant under the trade name Hostacerin® AMPS (CTFA name: ammonium polyacryldimethyltauramide). a. acrylamide and AMPS® copolymers, in particular crosslinked anionic acrylamide and AMPS® copolymers. These copolymers can be crosslinked with an unsaturated polyolefin compound such as those selected from the group consisting of tetraallyloxyethane, allyl pentaerythritol, methylenebisacrylamide, allyl sucrose, and pentaerythritol. Methylenebisacrylamide is preferred, partially or completely neutralized with a neutralizing agent such as sodium hydroxide, potassium hydroxide, aqueous ammonia, or an amine such as triethanolamine. Preferably, said unsaturated polyolefinic compound is present in the copolymer at a concentration between 0.06 and 1 mmol per mole of the monomer mixture. The preferred copolymers are obtained by radical copolymerization of 15-85 mol% acrylamide and 15-85 mol% 2-acrylamido-2-methylpropanesulfonic acid, in particular of 30-70 mol% acrylamide and 30-70 mol% 2-acrylamido-2-methylpropanesulfonic acid, and better still of 55-70 mol% acrylamide and 30-45 mol% 2-acrylamido-2-methylpropanesulfonic acid. In addition, 2-acrylamido-2-methylpropanesulfonic acid can usually be at least partially neutralized in the form of a salt, for example with sodium hydroxide, with potassium hydroxide or with a low molecular weight amine such as triethanolamine, or mixtures thereof. The hydrophilic polymer that can be used can also be chosen from crosslinked anionic copolymers of acrylamide and 2-acrylamido-2-methylpropanesulfonic acid. A crosslinked copolymer which is particularly preferred in the context of the implementation of the present invention is notably available under the name Sepigel® 305 sold by SEPPIC (CTFA name: polyacrylamide / C13-14 isoparaffin / Laureth 7); We can also mention the product Simulgel® 600 (CTFA name: acrylamide / sodium acryloyldimethyltaurate copolymer / isohexadecane / polysorbate 80) sold by SEPPIC.

[0143] 4) polysaccharides

[0144] Examples of polysaccharides include:

[0145] - seaweed extracts, such as alginates, carrageenans and agar-agar, and their mixtures. Examples of carrageenans that can be cited include Satiagum UTC30® and UTC10® from the company Degussa; as for alginate, sodium alginate sold under the name Kelcosol® by the company ISP can be cited;

[0146] - gums, such as xanthan gum and guar gum and its derivatives non-ionic (hydroxypropyl guar), gum arabic, konjac gum or mannan gum, tragacanth gum, ghatti gum, karaya gum or locust bean gum; examples that can be cited include guar gum sold under the name Jaguar HP 105® by the company Rhodia; mannan and konjac gum® (1% gluconomannan) sold by the company GfN;

[0147] - modified or unmodified starches, such as those obtained, for example, from cereals, such as wheat, maize or rice, legumes, such as blond peas, tubers, such as potatoes or cassava, and tapioca starches; dextrins, such as maize dextrins; examples that may be cited include Remy DR I® rice starch sold by the Remy company; Roquette B® maize starch; potato starch modified with 2-chloroethylaminodipropionic acid neutralized with sodium hydroxide, sold under the name Structure Solanace® by the National Starch company; original tapioca starch powder sold under the name Tapioca pure® by the National Starch company;

[0148] - dextrins, such as dextrin extracted from maize under the name Index® of the company National Starch;

[0149] - celluloses and their derivatives, in particular alkyl or hydroxyalkyl celluloses; Examples include methyl celluloses, hydroxyalkyl celluloses, ethyl hydroxyethyl celluloses and carboxymethyl celluloses. Examples that can be mentioned include cetyl hydroxyethyl celluloses sold under the names Polysurf 67CS® and Natrosol Plus 330® from Aqualon;

[0150] - and their mixtures.

[0151] 5) glyceryl acrylate polymers.

[0152] These glyceryl acrylate polymers are in particular selected from glyceryl acrylate and acrylic acid copolymers. Such copolymers are sold, in particular, under the names Lubrajel® MS, Lubrajel® CG, Lubrajel® DV, Lubrajel® NP, Lubrajel® Oil, Lubrajel® Oil BG, Lubrajel® PF, Lubrajel® TW, and Lubrajel® WA by Guardian Laboratories. Lubrajel® MS is preferred.

[0153] Preferably, the composition according to the invention comprises at least one hydrophilic polymer selected from: 1. homopolymers or copolymers of acrylic acid, which are preferably cross-linked, and their salts; 2. Polyacrylate salts; 3. 2-acrylamido-2-methylpropanesulfonic acid (AMPS®) polymers and copolymers, which are optionally crosslinked and / or neutralized, selected from:

[0154] a) Poly(2-acrylamido-2-methylpropanesulfonic acid) polymers, in particular homopolymers, polyAMPS®, which are crosslinked and neutralized to at least 90%;

[0155] b) acrylamide and AMPS® copolymers, in particular crosslinked anionic acrylamide and AMPS® copolymers; 1. Polysaccharides such as gums, especially xanthan gum.

[0156] More preferably, the composition according to the present invention comprises at least one hydrophilic polymer selected from 2-acrylamido-2-methylpropanesulfonic acid (AMPS®) homopolymers, which are optionally crosslinked and / or neutralized, polysaccharides, and their combinations.

[0157] More preferably, the composition according to the present invention comprises at least one hydrophilic polymer selected from ammonium polyacryloyldimethyltaurate, xanthan gum, and their combinations.

[0158] Advantageously, the hydrophilic polymer is present in the composition of the present invention in an amount ranging from 0.05% to 5% by weight, preferably from 0.1% to 3% by weight, more preferably from 0.15% to 2% by weight, even more preferably from 0.2% to 1% by weight, relative to the total weight of the composition. Aqueous phase

[0159] The composition of the present invention may include an aqueous phase.

[0160] Preferably, the aqueous phase comprises water.

[0161] Advantageously, water is present in the composition of the present invention in an amount ranging from 50% by weight to 99% by weight, preferably from 70% by weight to 97% by weight, more preferably from 80% by weight to 95% by weight, relative to the total weight of the composition.

[0162] Optionally, the aqueous phase comprises a water-miscible organic solvent (at room temperature 25 °C) selected from monoalcohols, glycols and polyols having from 2 to 20 carbon atoms, such as octyldodecanol, glycerin, propylene glycol, butylene glycol, pentylene glycol, hexylene glycol, caprylyl glycol, dipropylene glycol, diethylene glycol; and mixtures thereof.

[0163] Advantageously, the aqueous phase is present in the composition of the present invention in an amount ranging from 60% by weight to 99% by weight, preferably from 70% by weight to 97% by weight, more preferably from 80% by weight to 95% by weight, relative to the total weight of the composition. Additional cosmetic active ingredients

[0164] The composition of the present invention may include an additional cosmetic active ingredient in addition to the cosmetic active ingredients as defined above.

[0165] A person skilled in the art can adjust the type and quantity of additional cosmetic active ingredients according to the end use of the composition according to the present invention. Additional adjuvants or additives

[0166] The composition of the present invention may also contain conventional cosmetic adjuvants or additives, for example, perfumes, chelating agents, preservatives and bactericides, pH regulators, and mixtures thereof.

[0167] A person skilled in the art can choose the quantity of additional adjuvants or additives so as not to have a negative impact on the final use of the composition according to the present invention.

[0168] According to a particularly preferred embodiment, the present invention proposes a composition comprising, relative to the total weight of the composition: i. from 0.001 wt% to 0.5 wt% of copper tripeptide-1; ii. 0.5% by weight to 5% by weight of hydroxypropyl tetrahydropyrantriol; and iii. from 0.05% by weight to 1% by weight of at least one of the sesquistearate of methyl glucose, PEG-20 methyl glucose sesquistearate, polyglyceryl-3 methyl glucose distearate, and their combinations. pharmaceutical form and process

[0169] The composition of the present invention is in the form of an emulsion, a cream, a lotion or a hydrogel, and can be used as a toner, a lotion, a light cream, a nourishing cream, a night mask or an eye cream.

[0170] The composition of the present invention is stable at room temperature, preferably even at high temperature, and preferably has a translucent appearance.

[0171] As used herein, "stable at room temperature" means that the composition does not show any obvious change in appearance after being centrifuged at 900 rpm for 1 hour at room temperature (25°C).

[0172] As used herein, "high temperature stable" means that the composition does not show any obvious change in appearance at 45°C for at least 2 months and at 55°C for 10 days.

[0173] As used here, "translucent" means that the composition is neither transparent nor milky.

[0174] The composition of the present invention can be used for the care of keratinous materials. In particular, the composition of the present invention can deliver an anti-aging effect on the skin.

[0175] According to the second aspect, the present invention proposes a non-therapeutic method for the treatment of keratinous materials, comprising the application of the composition according to the first aspect of the present invention to the keratinous materials.

[0176] In certain embodiments, the present invention proposes a non-therapeutic method for resisting skin aging, comprising applying the composition according to the first aspect of the present invention to the skin. EXAMPLES

[0177] The following examples are given by way of non-limiting illustrations of the present invention.

[0178] The main raw materials used, their trade names and suppliers are listed in Table 4.

[0179] [Tables4] INCI Name Trade Name Supplier Copper Tripeptide-1 GHK-CU SPECIFIE (1.0%) SPECCHEM IN DUSTRY Hydroxypropyl Tetrahydropyrantriol MEXORYL SCS NOVEAL Ammonium Polyacryloyldimethyl Taurate HOSTACERIN AM PS CLARIANT Xanthan Gum KELTROL CG-T CP KELCO Methyl Glucose Sesquistearate PEG-20 GLUCAMATE SSE-20 EMULSIFIER LUBRIZOL Methyl Glucose Sesquistearate GLUCATE SS EM ULSIFIER LUBRIZOL Polyglyceryl e-3 methylglucose distearate TEGO CARE 450 MB EVONIK GOLD SCHMIDT PEG-20 stearate SP MYRJ S20 MBA L-PA-(MV) CRODA PPG-6-decyltetradeceth-30 NIKKOL SG-DTD630 NIPPON SURFA CTANT INDUS TRIES

[0180] Inventive Examples 1-3 and Comparative Examples 1-3

[0181] Compositions of inventive examples (El) 1-3 and comparative examples (EC) 1-3 were prepared on the basis of the quantities given in Table 5. The quantities are given as a percentage by weight of each component relative to the total weight of the composition, MA meaning active substance.

[0182] [Tables5] Components EI.1 EL2 EI.3 EC.1 EC.2 EC.3 Copper tripeptide-1 0.015 (MA) 0.015 (MA) 0.015 (MA) 0.015 (MA) 0.015 (MA) 0.015 (MA) Hydroxypropyl tetrahydropyrantriol 3 (MA) 3 (MA) 3 (MA) 3 (MA) 3 (MA) 3 (MA) PEG-20 methyl glucose sesquistearate 0.1 - - - - - Methyl glucose sesquistearate - 0.1 - - - - Polyglyceryl-3 methylglucose distearate - - 0.1 - - - PPG-6-decyltetradeceth-30 - - - - 0.1 - PEG-20 stearate - - - - - 0.1 Polyacryloyldimethyl Ammonium taurate 0.25 0.25 0.25 0.25 0.25 0.25 Xanthan gum 0.1 0.1 0.1 0.1 0.1 0.1 Octyldodecanol 0.5 0.5 0.5 0.5 0.5 0.5 Water QS100 QS100 QS100 QS100 QS100 QS100

[0183] The compositions of inventive examples 1-3 represent a composition according to the present invention.

[0184] The composition of comparative example 1 does not include sugar fatty acid ester or oxyalkylated ether thereof.

[0185] The composition of comparative example 2 includes PPG-6-decyltetradeceth-30 in place of a sugar fatty acid ester or an oxyalkylated ether thereof.

[0186] The composition of comparative example 3 includes PEG-20 stearate instead of a sugar fatty acid ester or an oxyalkylated ether thereof.

[0187] Preparation process:

[0188] The compositions listed above were prepared as follows: 1. Addition of ammonium polyacryloyldimethyl taurate, xanthan gum, octyldodecanol and surfactants (PEG-20 methyl glucose sesquistearate, methyl glucose sesquistearate, polyglyceryl-3 methyl glucose distearate, PPG-6-decyltetradeceth-30, PEG-20 stearate) as appropriate in the corresponding amounts in Table 2 slowly in water with stirring to obtain a mixture; 2. heating the mixture to over 70 °C until the polymers are completely dispersed and the mixture becomes a viscous solution; 3. Cooling the solution to room temperature (approximately 20 °C); 4. Adding copper tripeptide-1 and hydroxypropyl tetrahydropyrantriol with stirring to obtain a homogeneous solution. Assessment

[0189] The appearance and stability of the above-prepared compositions were evaluated as follows. Appearance

[0190] The appearance of the above-prepared compositions was observed with the naked eye immediately after their preparation and the application of a drop of each composition to the back of the hands. Stability at room temperature

[0191] The stability at room temperature of the compositions prepared above was evaluated as follows.

[0192] Approximately 20 g of the sample to be evaluated were placed in a centrifuge tube and centrifuged at 900 rpm for 1 hour at room temperature (25 °C).

[0193] The centrifuged sample was compared to the original sample in terms of appearance. If the centrifuged sample is identical to the original sample (uniform phase), it will be considered to have passed the stability test. If the centrifuged sample is different from the original sample (for example, separated into two phases or containing sediment), it will be considered to have failed the stability test. High temperature stability

[0194] The high-temperature stability of the above-prepared compositions was determined by placing them at 45°C for 2 months and 55°C for 10 days, respectively, and then evaluating their appearance.

[0195] In the absence of phase separation, oil droplet breakup, oil droplet size increase, or non-aggregation after storage at 45°C for 2 months and 55°C for 10 days, the test composition will be considered to have successfully passed the stability test. Otherwise, the test composition will not be considered to have successfully passed the stability test.

[0196] The stability of each composition tested has been summarized in Table 6.

[0197] [Tableauxô] Properties ELI EI.2 EI.3 EC.1 EC.2 EC.3 Appearance Translucent Translucent Milky Translucent Stability at room temperature Success Success Success Failure Failure Failure Stability at high temperatures Success ND ND ND ND ND

[0198] ND-not determined.

[0199] It can be seen from Table 6 that the compositions of inventive examples 1-3 are stable at room temperature and have a translucent appearance, the composition of inventive example 1 is stable even at high temperature.

Claims

Demands

1. Composition comprising: (i) at least one copper peptide complex; (ii) at least one C-glycoside; and (iii) a sugar fatty acid ester and / or an oxyalkylated ether thereof.

2. Composition according to claim 1, wherein the copper peptide complex is selected from glycyl-histidyl-lysine: copper, glycyl-arginyl-lysine: copper, glycyl-(3-methyl)histidyl-lysine: copper, glycyl-(5-methyl)histidyl-lysine: copper, alanyl-histidyl-lysine: copper, alanyl-arginyl-lysine: copper, alanyl-(3-methyl)histidyl-lysine: copper, alanyl-(5-methyl)histidyl-lysine: copper, glycyl-histidyl-phenylalanine: copper, glycyl-arginyl-phenylalanine: copper, glycyl-(3-methyl)histidyl-phenylalanine: copper, glycyl-(5-methyl)histidyl-phenylalanine: copper, alanyl-histidyl-phenylalanine: copper, alanyl-arginyl-phenylalanine: copper, alanyl-(3-methyl)histidyl-phenylalanine: copper, alanyl-(5-methyl)histidyl-phenylalanine: copper, (N-methyl)glycyl-histidyl-lysine: copper, (N-methyl)glycyl-arginyl-lysine: copper, valyl-histidyl-lysine: copper, prolyl-histidyl-lysine: copper, leucyl-histidyl-lysine: copper, glycyl-D-histidyl-L-lysine: copperSeryl-histidyl-lysine-lysine: copper, and their combinations: preferably selected from L-alanyl-L-histidyl-L-lysine: copper(II), L-valyl-L-histidyl-L-lysine: copper(II), glycyl-L-histidyl-L-lysine: copper(II), and their combinations; more preferably, the copper peptide complex is copper tripeptide-1.

3. Composition according to any one of claims 1 to 2, wherein the copper peptide complex is present in an amount ranging from 0.00001% by weight to 10% by weight, preferably from 0.0005% by weight to 5% by weight, preferably from 0.001% by weight to 1% by weight, even more preferably from 0.001% by weight to 0.5% by weight, even more preferably from 0.003% by weight to 0.3% by weight, most preferably from 0.005% by weight to 0.2% by weight, relative to the total weight of the composition.

4. Composition according to any one of claims 1 to 3, wherein the C-glycoside is selected from - C-[3-D-xylopyranoside-n-propan-2-one, - C-a-D-xylopyranoside-n-propan-2-one, - C-[3-D-xylopyranoside-2-hydroxypropane, - C-a-D-xylopyranoside-2-hydroxypropane, - l-(C-[3-D-fucopyranoside)propan-2-one, - l-(C-a-D-fucopyranoside)propan-2-one, - 1 -(C- [3-L-fucopyranoside)propan-2-one, - l-(C-a-L-fucopyranoside)propan-2-one, - l-(C-[3-D-fucopyranoside)-2-hydroxypropane, - l-(C-a-D-fucopyranoside)-2-hydroxypropane, - l-(C-[3-L-fucopyranoside)-2-hydroxypropane, - l-(C-a-L-fucopyranoside)-2-hydroxypropane, - l-(C-[3-D-glucopyranosyl)-2-hydroxypropane, - l-(C-a-D-glucopyranosyl)-2-hydroxypropane, - l-(C-[3-D-galactopyranosyl)-2-hydroxypropane, - l-(C-a-D-galactopyranosyl)-2-hydroxypropane, - 1 -(C- [3-D-fucofuranosyl)propan-2-one, - l-(C-a-D-fucofuranosyl)propan-2-one, - l-(C-[3-L-fucofuranosyl)propan-2-one, - l-(C-a-L-fucofuranosyl)propan-2-one, - C-[3-D-maltopyranoside-n-propan-2-one, - C-a-D-maltopyranoside-n-propan-2-one, - C-[3-D-maltopyranoside-2-hydroxypropane, - C-a-D-maltopyranoside-2-hydroxypropane,their isomers and mixtures.

5. Composition according to any one of claims 1 to 4, wherein the C-glycoside is present in an amount from 0.01% by weight to 20% by weight, preferably from 0.1% by weight to 15% by weight, more preferably from 0.3% by weight to 10% by weight, even more preferably from 0.5% by weight to 5% by weight, relative to the total weight of the composition.

6. A composition according to any one of claims 1 to 5, wherein the sugar fatty acid ester and / or an oxyalkylated ether thereof is selected from linear or branched (alkyl)glucose and C6-C30 fatty acid esters, saturated or unsaturated, and their oxyethylated ethers, preferably selected from linear or branched C12-C22 fatty acid methyl esters, saturated or unsaturated, and their ethoxylated and / or propoxylated ethers; more preferably, the composition comprises at least one of sesquistearate methyl glucose, PEG-20 methyl glucose sesquistearate, polyglyceryl-3 methylglucose distearate, and their combinations.

7. Composition according to any one of claims 1 to 6, wherein the sugar fatty acid ester and / or its oxyalkylated ether is present in an amount from 0.01% by weight to 10% by weight, preferably from 0.02% by weight to 5% by weight, more preferably from 0.05% by weight to 3% by weight, even more preferably from 0.05% by weight to 1% by weight, relative to the total weight of the composition.

8. Composition according to claim 1, comprising, relative to the total weight of the composition: (i) 0.001% by weight to 0.5% by weight of copper tripeptide-1; (iii) 0.5% by weight to 5% by weight of hydroxypropyl tetrahydropyrantriol; and (iv) 0.05% by weight to 1% by weight of at least one of methyl glucose sesquistearate, PEG-20 methyl glucose sesquistearate, polyglyceryl-3 methyl glucose distearate, and combinations thereof.

9. A composition according to any one of claims 1 to 8, further comprising one or more hydrophilic polymers, preferably selected from: 1) acrylic acid homopolymers or copolymers, preferably crosslinked, and their salts; 2) polyacrylate salts; 3) 2-acrylamido-2-methylpropanesulfonic acid (AMPS) polymers and copolymers, optionally crosslinked and / or neutralized, selected from: a) poly(2-acrylamido-2-methylpropanesulfonic acid) polymers, in particular homopolymers, polyAMPS, which are crosslinked and neutralized to at least 90%; b) acrylamide and AMPS copolymers, in particular crosslinked anionic acrylamide and AMPS copolymers; 4) polysaccharides.

10. Non-therapeutic method for the treatment of keratinous materials, comprising the application of the composition according to any one of claims 1 to 9 on keratinous materials.